For years, people taking GLP-1 type drugs (e.g., Ozempic, Wegovy) have noticed that the medicines didn’t just help them to ...

A phase 2 trial shows significant reduction in drinks per drinking day and weekly alcohol craving with low-dose semaglutide. HealthDay News — Low-dose semaglutide seems to reduce craving and certain ...

While more research is needed, experts consider semaglutide a promising development in addressing alcohol addiction.

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

For many Americans, St. Patrick’s Day is a moment to don green apparel and indulge in drinking a few – or more than a few – ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...